Evidence map›Paper›PMID 38699594›Full record

ArticleJournal of inflammation research2024

Redox Biomarkers - An Effective Tool for Diagnosing COVID-19 Patients and Convalescents.

Blanka Wolszczak-Biedrzycka, Justyna Dorf, Joanna Matowicka-Karna, Violetta Dymicka-Piekarska, Marzena Wojewódzka-Żeleźniakowicz, Piotr Żukowski, Anna Zalewska, Łukasz Dąbrowski, Mateusz Maciejczyk

Abstract read
In one paragraph

Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Blanka Wolszczak-BiedrzyckaDepartment of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.ORCID 0000-0003-4724-4689
Justyna DorfDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0003-2391-3307
Joanna Matowicka-KarnaDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0003-4438-9110
Violetta Dymicka-PiekarskaDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0003-4170-0997
Marzena Wojewódzka-ŻeleźniakowiczDepartment of Emergency Medicine and Disasters, Medical University of Bialystok, Bialystok, Poland.
Piotr ŻukowskiDepartment of Restorative Dentistry, Croydon University Hospital, London, UK.
Anna ZalewskaIndependent Laboratory of Experimental Dentistry, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0003-4562-0951
Łukasz DąbrowskiMedical Laboratory, "Diagnostyka" Olsztyn, Olsztyn, Poland.
Mateusz MaciejczykDepartment of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0001-5609-3187

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: COVID-19 triggers the overproduction of reactive oxygen species (ROS) which, in combination with a weakened antioxidant barrier, can lead to protein oxidation and lipid peroxidation. The aim of this study was to evaluate enzymatic and non-enzymatic antioxidants, the overall redox potential, and protein and lipid peroxidation products in COVID-19 patients, convalescents, and healthy subjects, and to the determine the diagnostic applicability of these parameters in COVID-19 patients. Materials and Methods: The study involved 218 patients with COVID-19, 69 convalescents, and 48 healthy subjects who were selected for the research based on age and sex. The study was conducted between 20 February 2021 and 20 November 2021 in Białystok, Poland. The antioxidant barrier, redox status, and oxidative damage products were assessed in serum/plasma samples with the use of colorimetric and spectrophotometric assays. Results: Glutathione reductase (GR) activity was higher, whereas total antioxidant capacity (TAC) was lower in COVID-19 patients than in convalescents (p<0.0001) and the control group (p<0.0001). The concentrations of advanced glycation end products (AGEs), advanced oxidation protein products (AOPP), 4-hydroxynonenal (4-HNE), and malondialdehyde (MDA) were higher in COVID-19 patients (p<0.0001) and convalescents (p<0.0001) than in the control group. AGEs were the most effective diagnostic biomarker for differentiating COVID-19 patients from the control group (AUC=0.9971) and convalescents from the control group (AUC=1.000). Conclusion: An infection with the SARS-CoV-2 disrupts the redox balance and increases protein oxidation and lipid peroxidation. AGEs fulfill the criteria for a potential diagnostic biomarker in COVID-19 patients and convalescents.

Indexed as

antioxidantsCOVID-19oxidative stressredox biomarkersSARS CoV-2 virus

Identifiers

PMID38699594
PMCPMC11063110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.